COVID-19-Associated Retroperitoneal Hemorrhage: Same Complication, Two Different Types of Treatment

Yoldemir, Şengül Aydin; Akıllı, Işıl Kibar; Bilge, Müge; Ünlü, Esra Canbolat; Güner, Şebnem İzmir; Güner, Ekrem; Yaşar, Kadriye Kart

doi:10.5222/gju.2021.79188

Cited by 2 publications

(2 citation statements)

References 12 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most important cause of death in COVID-19 patients is thromboembolism due to the cytokine storm and altered coagulation profiles of the patients [1,8,9]. To avoid this complication, the authors have recommended anticoagulation treatment [10,11]. However, there is no standard dose that can provide a totally safe environment for patients because the clinic of each patient is unique, and the predisposition to this complication may vary [5,10].…”

Section: Discussionmentioning

confidence: 99%

The Retrospective Analysis of 54 COVID-19 Patients With Retroperitoneal Bleeding in One Center

Kasap¹,

Polat²,

Ceviz³

et al. 2022

Grand J Urol

View full text Add to dashboard Cite

Objective: We aimed to analyze and report the outcomes of patients with retroperitoneal bleeding (RPB) among our COVID-19 inpatients under anticoagulation therapy. Materials and Methods: We retrospectively analyzed 54 patients who were anticoagulated with low-molecular-weight heparin (LMWH) and developed RPB during COVID-19 treatment in the hospital, either in intensive care unit or non-intensive care unit services, between March 2020 and March 2021. The patients' demographic and clinical data were analyzed, and we compared the laboratory results at the time of admission and during episodes of RPB. The patients were divided into conservative and interventional treatment groups. We compared the size of retroperitoneal hematoma, anticoagulant doses, erythrocyte suspension transfusion rates, presence of hyperinflammation syndrome between these groups. Also, treatment modalities and mortality status were shown. The hematoma size and erythrocyte suspension transfusion rates were compared between groups, and their correlation with anticoagulant dose and age were analyzed as well. Results: In the management of RPB that developed, 48 (88.9%) patients were approached conservatively, 4 (7.4%) patients underwent angioembolization, and 2 (3.7%) patients laparotomy. Mortality was observed in 14 (25.9%) patients. Relevant laboratory parameters as lactate dehydrogenase, procalcitonin, interleukin-6 levels and lymphocyte counts were elevated exceedingly, while the hemoglobin values were significantly lower during episodes of RPB (p=0.007, p=0.044, p=0.031, p=0.018 and p<0.001, respectively). Also, there was a significant correlation between increased LMWH doses and size of the hematomas (p=0.044). Conclusion: Patients experiencing RPB while receiving anticoagulants due to COVID-19 need active treatment depending on the dose of anticoagulants they are using. Considering the patient's clinical need, it may be a logical approach to start treatment with the lowest possible dose of an anticoagulant.

show abstract

Section: Discussionmentioning

confidence: 99%

The Retrospective Analysis of 54 COVID-19 Patients With Retroperitoneal Bleeding in One Center

Kasap¹,

Polat²,

Ceviz³

et al. 2022

Grand J Urol

View full text Add to dashboard Cite

show abstract

“…In the pathophysiology of COVID‐19, there is a cytokine storm caused by hyperinflammation and immunosuppression and the resulting microthrombosis and disseminated intravascular coagulation (DIC) development (Jose & Manuel, 2020 ; Tay et al, 2020 ). Although the lungs are the first and most affected organs by this cytokine storm, studies have shown that the whole body, especially the cardiovascular system, is affected due to bleeding and coagulation at multiple levels such as endothelial damage, microangiopathy and vasculitis (Aydın Yoldemir et al, 2021 ; Menter et al, 2020 ). Studies have shown that endothelial dysfunction, subclinical hypogonadism, anxiety and impaired cardiac and pulmonary haemodynamics may develop with COVID‐19, which may contribute to the emergence of ED (Kresch et al, 2021 ; Sansone et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

A factor not to be ignored in post‐COVID ‐19 erectile dysfunction; psychological effect, a prospective study

Sevim¹,

Alkış²,

Kartal³

et al. 2022

Andrologia

View full text Add to dashboard Cite

It was aimed to show the effect of anxiety and depression on erectile dysfunction seen after coronavirus disease‐2019 (COVID‐19). Between March and July 2021, the participants completed the International Index of Erectile Function, Beck Depression Inventory and Generalised Anxiety Disorder 7 forms at the beginning and after the 1st month of the disease. We investigated the psychological impact of COVID‐19 on the development of erectile dysfunction. The mean age of 156 male patients in the study was 54.74 ± 8.01 years. It was determined that the mean International Index of Erectile Function scores of the patients before COVID‐19 were 73.42 ± 3.43 and decreased to 68.28 ± 12.86 after COVID‐19 ( p < .01). The patients’ erectile function scores were significantly lower after COVID‐19 (29.45 ± 1.23, 27.69 ± 4.33, p < .01, respectively). Their Beck Depression Inventory scores were statistically significantly higher after COVID‐19 (1.69 ± 2.56, 2.22 ± 2.79, p < .01, respectively). Their Generalised Anxiety Disorder 7 scores were also statistically significantly higher after COVID‐19 (4.69 ± 1.63 6.56 ± 2.40, p < .01, respectively). A negative correlation was found between the increase in the Beck Depression Inventory score during the pandemic process and the decrease in the International Index of Erectile Function score ( r = −0.356, p = <.001). A negative correlation was also found between the increase in the Generalised Anxiety Disorder 7 score and the decrease in the International Index of Erectile Function score ( r = −0.200, p = .012). One of the main factors post‐COVID‐19 erectile dysfunction is anxiety and depression due to the disease.

show abstract

COVID-19-Associated Retroperitoneal Hemorrhage: Same Complication, Two Different Types of Treatment

Cited by 2 publications

References 12 publications

The Retrospective Analysis of 54 COVID-19 Patients With Retroperitoneal Bleeding in One Center

The Retrospective Analysis of 54 COVID-19 Patients With Retroperitoneal Bleeding in One Center

A factor not to be ignored in post‐COVID ‐19 erectile dysfunction; psychological effect, a prospective study

Contact Info

Product

Resources

About